Study of Risk Factors for Intraductal Papillary Mucinous Neoplasms Degeneration at the Nancy CHRU (IPMN)

Sensitivity and Specificity Study of Risk Factors for Intraductal Papillary Mucinous Neoplasms Degeneration at the Nancy CHRU (IPMN)

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04901364

Acronym

IPMN

Enrollment

Registered

2021-05-25

Start date

2021-05-10

Completion date

2021-10-30

Last updated

2021-05-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Study of Risk Factors for IPMNs Degeneration at the Nancy CHRU

Keywords

IPMNs, Intraductal Papillary Mucinous Neoplasms

Brief summary

Cystic lesions of the pancreas are frequent with a risk of degeneration into adenocarcinoma with pejorative prognosis. IPMNs require characterization to clarify their potential for degeneration. Clinical and morphological risk factors for degeneration determine the monitoring rate and the indication for pancreatic surgery. Pancreatic surgery remains invasive with high morbidity and mortality rates.

Detailed description

This is a monoservice and monocentric retrospective study at the Nancy CHRU. We will study the risk factors for IPMNs degeneration in order to determine the most sensitive and specific. To do this, we will use high-grade dysplasia or invasive cancer on the histological analysis of surgical specimens as the primary endpoint. The study population will be patients with Branch Duct, Main Duct or mixed IPMNs operated at the Nancy CHRU between September 2009 and October 2021.

Interventions

BEHAVIORALSensitivity and specificity of risk factors for degeneration of IPMNs

Measurement of high-grade dysplasia or invasive cancer on the histological analysis of the surgical specimen

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients with a Branch Duct, Main Duct or mixed IPMNs operated at the Nancy CHRU between September 2009 and October 2021, adults and without legal protection measures

Exclusion criteria

* IPMNs not operated * Pancreatic cancer without IPMNs * Patients whose state of health contraindicates pancreatic surgery * Non-adult patient * Patients under legal protection

Design outcomes

Primary

Measure	Time frame	Description
High-grade dysplasia or invasive cancer	12 years	High-grade dysplasia or invasive cancer on histological analysis of the surgical specimen

Countries

France

Contacts

Primary ContactRemy RF FONTANIE

remyfontanie@yahoo.fr0616297216

Backup ContactMarion MS SCHAEFER

m.schaefer@chru-nancy.fr0642743330

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026